HK1204992A1 - 含有舒尼替尼的局部眼科藥物組合物 - Google Patents

含有舒尼替尼的局部眼科藥物組合物

Info

Publication number
HK1204992A1
HK1204992A1 HK15105934.1A HK15105934A HK1204992A1 HK 1204992 A1 HK1204992 A1 HK 1204992A1 HK 15105934 A HK15105934 A HK 15105934A HK 1204992 A1 HK1204992 A1 HK 1204992A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition containing
ophthalmological pharmaceutical
topical ophthalmological
containing sunitinib
Prior art date
Application number
HK15105934.1A
Other languages
English (en)
Inventor
Michael Bttger
Degenfeld Georges Von
Julia Freundlieb
Claudia Hirth-Dietrich
Joerg Keldenich
Jrgen Klar
Uwe Muenster
Andreas Ohm
Annett Richter
Bernd Riedl
Joachim Telser
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/062365 external-priority patent/WO2013000917A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1204992A1 publication Critical patent/HK1204992A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15105934.1A 2012-06-25 2015-06-23 含有舒尼替尼的局部眼科藥物組合物 HK1204992A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PK40512 2012-06-25
PCT/EP2012/062365 WO2013000917A1 (en) 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib
JOP20120170 2012-06-27
VE81612 2012-06-27
EP12198651 2012-12-20
PCT/US2013/044953 WO2013188283A1 (en) 2012-06-12 2013-06-10 Topical ophthalmological pharmaceutical composition containing sunitinib

Publications (1)

Publication Number Publication Date
HK1204992A1 true HK1204992A1 (zh) 2015-12-11

Family

ID=49758933

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105934.1A HK1204992A1 (zh) 2012-06-25 2015-06-23 含有舒尼替尼的局部眼科藥物組合物

Country Status (7)

Country Link
US (1) US20150174096A1 (zh)
EP (1) EP2858628A1 (zh)
JP (1) JP2017512748A (zh)
CN (1) CN104582685A (zh)
CA (1) CA2876311A1 (zh)
HK (1) HK1204992A1 (zh)
WO (1) WO2013188283A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4445952A2 (en) * 2014-12-15 2024-10-16 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
KR20240043821A (ko) 2015-06-06 2024-04-03 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
TWI700085B (zh) 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
AU2016353355B9 (en) 2015-11-12 2022-09-29 Graybug Vision, Inc. Aggregating microparticles for therapy
CA3025325A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257487A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
CN101163473A (zh) * 2005-05-12 2008-04-16 辉瑞大药厂 使用舒尼替尼苹果酸盐的抗癌组合疗法
EP1893216A4 (en) 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
CA2631173A1 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment method
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
BR112012001030A2 (pt) 2009-07-16 2019-09-24 Glaxo Wellcome Mfg Pte Ltd método para tratar a degeneração macular, e, uso de um composto.
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.

Also Published As

Publication number Publication date
CN104582685A (zh) 2015-04-29
JP2017512748A (ja) 2017-05-25
EP2858628A1 (en) 2015-04-15
US20150174096A1 (en) 2015-06-25
WO2013188283A1 (en) 2013-12-19
WO2013188283A8 (en) 2017-03-23
CA2876311A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
HK1206297A1 (zh) 用於聯合療法的藥物組合物
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
ZA201501930B (en) Pharmaceutical composition
HK1204564A1 (zh) 含有阿昔替尼的局部眼科藥物組合物
HK1204563A1 (zh) 含有帕唑帕尼的局部眼科藥物組合物
HK1204992A1 (zh) 含有舒尼替尼的局部眼科藥物組合物
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
IL266415A (en) Innovative pharmaceutical composition
HK1197176A1 (zh) 含有瑞格非尼的局部眼用藥物組合物
HK1210711A1 (zh) 包含瑞巴派特的藥物組合物
ZA201505196B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1204289A1 (zh) 含有西地尼布的局部眼科藥物組合物
ZA201502987B (en) Pharmaceutical composition
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
EP2883546A4 (en) NOVEL DIFFERENTIALLY RELEASING PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE INGREDIENTS
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
ZA201400751B (en) Pharmaceutical composition
AU2012904295A0 (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition